TLR9 Agonist, but Not TLR7/8, Functions as an Adjuvant to Diminish FI-RSV Vaccine-Enhanced Disease, While Either Agonist Used as Therapy During Primary RSV Infection Increases Disease Severity
Vaccine - Netherlands
doi 10.1016/j.vaccine.2009.03.026
Full Text
Open PDFAbstract
Available in full text
Categories
Date
May 1, 2009
Authors
Publisher
Elsevier BV